Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CESSHYDRO: Early vs Conventional Hydrocortisone Cessation in Septic Shock
NCT05818826Phase 2Recruiting
- Sponsor
- Mahidol University
- Start
- Jul 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hydrocortisone in septic shock (2 arms), sponsored by Mahidol University. Primary endpoint: Composite adverse events of early versus conventional cessation of hydrocortisone at 14 days. Started Jul 2023; status: recruiting.
02
Drugs
hydrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05818826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818826.